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Objectives The purpose of this study was to evaluate the long-term safety and effectiveness of
drug-eluting stents (DES) for the treatment of saphenous vein graft (SVG) disease.
Background DES are frequently implanted for SVG interventions, but some studies have shown that
they are not effective in reducing target vessel revascularization (TVR) over longer-term follow-up.
Some studies suggest there is increased mortality with DES compared with bare-metal stents (BMS).
Methods We performed propensity score matching analysis using a population-based cohort that in-
cluded 709 well-matched pairs (n  1,418) who received DES or BMS for the treatment of SVG disease
from 2003 to 2008. Outcomes of interest included repeat TVR, myocardial infarction, and death.
Results The mean age of the propensity-matched cohort was 69 years, 50% had diabetes, and the
mean age of SVG was 10.6 years. At 4-year follow-up, the rate of repeat TVR was 21% in the DES
group and 27.6% in the BMS group (p  0.004). DES implantation was associated with the largest
TVR reduction among patients with diabetes and patients receiving longer stents (30 mm) and the
number of procedures needed to prevent a TVR at 4 years was 8 and 7, respectively. The composite
rate of myocardial infarction or death was not signiﬁcantly different between DES and BMS at
4 years (27.8% vs. 32.6%, p  0.09).
Conclusions Implantation of DES in the treatment of SVG disease is associated with substantial re-
duction of repeat revascularization, without evidence of an increased risk of myocardial infarction or
death at longer-term follow-up. (J Am Coll Cardiol Intv 2011;4:965–73) © 2011 by the American
College of Cardiology Foundation
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966Drug-eluting stents (DES) have been demonstrated to be
safe and highly effective in reducing the need for repeat
coronary revascularization in native coronary vessels and
have been adopted to the routine practice of interventional
cardiology (1–3). Although it is hoped that the benefits of
DES can be extended to the treatment of saphenous vein
graft (SVG) lesions, there are existing concerns and contro-
versies regarding the safety and effectiveness of DES in the
treatment of SVG disease (4,5). In the RRISC (Reduction
of Restenosis in Saphenous Vein Grafts with Cypher Stent)
trial (6,7), substantially higher rates of death were seen
among patients treated with DES compared with bare-
metal stents (BMS) (29% in the DES group vs. 0% in the
BMS group) during a median follow-up of 32 months. The
recently published long-term follow-up of the SOS (Stent-
ing of Saphenous Vein Grafts) trial (8) also showed in-
creased in all-cause mortality associated with DES (24% in the
ES group vs. 13% in the BMS group) that did not reach
tatistical significance. Although several observational studies
(9–11) and meta-analyses (12–14)
have reported no increased risks of
death or recurrent myocardial in-
farction associated with DES im-
plantation in SVG disease, limita-
tions of these studies have even led
study investigators to urge cautious
interpretation of their findings.
In the 25 studies (3 random-
ized, 22 observational) that as-
sessed DES for the treatment of
SVG disease, only 7 studies as-
sessed longer-term outcomes of
more than 30 months (13). All 7
studies were single-center co-
horts, which raised concerns re-
garding the generalizability of the findings. Only 1 of 25
studies evaluated more than 500 patients in the DES group
(13). Although meta-analyses can increase the accuracy of
estimates, this statistical technique cannot eliminate selec-
tion biases inherent to these small observational studies
(15). Finally, several studies have suggested a “catch up”
phenomenon whereby the early benefits of DES in reducing
repeat revascularization are attenuated over time, and that
DES are no longer more effective than BMS at longer term
(7,9,16). Yet, very few studies have adjusted for the potential
difference in the degree of degeneration in SVGs, thus poten-
tially biasing against the DES group at longer-term because
they are often implanted among patients with higher risk of
disease progression.
In the United States, it is estimated that SVG interven-
tions account for 5% to 10% of the total number of
percutaneous coronary interventions (PCI) performed each
year (12). Addressing these gaps in knowledge may have a
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass graft
CCN  Cardiac Care
Network of Ontario
DES  drug-eluting stent(s)
PCI  percutaneous
coronary intervention
SVG  saphenous vein graft
TVR  target vessel
revascularizationsignificant impact on the practice of interventional cardiol-ogy. The availability of a large population-based PCI
database in Ontario, Canada, afforded a unique opportunity
to conduct 1 of the largest and most comprehensive studies
to evaluate the long-term safety and effectiveness of DES
versus BMS in patients undergoing SVG interventions.
Methods
Data sources. The Cardiac Care Network (CCN) of On-
tario maintains an ongoing prospective clinical registry of all
patients undergoing cardiac catheterization, PCI, and cor-
onary artery bypass graft (CABG) surgery (17,18). Since the
introduction of DES in late 2003, specific mandatory fields
such as stent type, size and diameter of each stent, and
location of stent placement were added. The Canadian
Institute for Health Information hospital discharge abstract
database was used to identify additional comorbid condi-
tions not captured in the CCN registry and to identify
repeat hospitalization after the index PCI procedure. The
Ontario Registered Persons Database was used to ascertain
mortality outcomes. Linkages of these large databases were
performed using unique encrypted patient identifiers to
protect patient confidentiality. The need for informed
patient consent was waived because participation is manda-
tory under Ontario’s legislation regarding the privacy of
health information. This study was approved by the research
ethics board at the Sunnybrook Health Sciences Centre.
Study sample. We identified an initial cohort of patients
who underwent stent implantation for the treatment of
SVG disease from December 1, 2003, to December 31,
2008. This time frame was chosen to allow for at least 1 year
of follow-up for each patient. From this initial cohort, we
excluded patients who had both DES and BMS during the
index PCI. We also excluded patients who had PCI or
CABG in the 12 months before the index procedure using
data from the CCN registry because of the concern that
there would not be a sufficient number of patients receiving
BMS to allow for propensity score matching. Patients who
did not have a valid Ontario health card number were also
excluded because their outcomes could not be determined.
Outcomes. The primary effectiveness outcome was repeat
target vessel revascularization (TVR). The primary safety
outcomes were myocardial infarction and all-cause mortal-
ity. Repeat TVR after the index PCI was determined using
information from the CCN database. Recurrent myocardial
infarction leading to hospitalization was assessed using the
Canadian Institute for Health Information discharge ab-
stract database (International Classification of Diseases-
10th revision, disease codes I21 and I22). Periprocedure
myocardial infarctions after PCI were not included in
outcome assessment. Mortality was determined from the
Ontario Registered Persons Database. Complete follow-up
data were available for each patient through March 31,
2010, for all outcomes of interest.
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967Statistical analysis. Propensity score matching analysis was
used to minimize the influence of potential confounding
and selection biases (17–20). We calculated the predicted
probability of DES implantation by fitting a logistic regres-
sion model using all the clinically relevant variables for stent
selection from clinical knowledge. As shown in Table 1,
these variables included demographics (age, sex), comor-
bidities (hypertension, diabetes, cerebrovascular disease,
Table 1. Baseline Characteristics of the Propensity-
Tot
Demographics
Age, yrs
65
65–74
75–84
85
Male
Admission characteristics
Recent AMI (same day as PCI)
Recent AMI (days 1–7)
Recent AMI (days 8–30)
No prior AMI within 30 days before PCI
CCS angina class before procedure
0
I
II
III
IV
Time from CABG to index PCI, yrs
1–5
5–10
10
Missing
Cardiac risk factors and comorbidities
Hypertension
Diabetes
Prior stroke or transient ischemic attack
Chronic obstructive pulmonary disease
Heart failure
Peripheral vascular disease
Cancer
Hemodialysis
Stent location
SVG to left anterior descending or diagonal
SVG to left circumﬂex
SVG to right coronary artery
Stent characteristics
Number of stents
Stent diameter
Stent length
Values are mean SD or n (%).
AMI  acute myocardial infarction; BMS  bare-metal stent(s); CDES drug-eluting stent(s); PCI percutaneous coronary intervention; SVGchronic obstructive pulmonary disease, heart failure, periph-
eral vascular disease, cancer, hemodialysis), admission char-
acteristics (angina classification, myocardial infarction), and
procedure characteristics (stent location, stent size, stent
length). We also adjusted for the age of SVGs by calculating
the time of CABG to index PCI as a surrogate for the
degree of SVG degeneration. A greedy, nearest-neighbor
1:1 matching algorithm was used to match patients, with
ed Study Cohort
 1,418) BMS (n  709) DES (n  709)
9.2 69.7 9.3 69.2 9.0
28.1%) 195 (27.5%) 204 (28.8%)
40.6%) 286 (40.3%) 289 (40.8%)
28.4%) 207 (29.2%) 196 (27.6%)
2.9%) 21 (3.0%) 20 (2.8%)
83.1%) 584 (82.4%) 594 (83.8%)
6.9%) 54 (7.6%) 44 (6.2%)
17.6%) 126 (17.8%) 123 (17.3%)
6.3%) 39 (5.5%) 50 (7.1%)
69.3%) 490 (69.1%) 492 (69.4%)
3.4%) 23 (3.2%) 25 (3.5%)
2.7%) 18 (2.5%) 20 (2.8%)
12.8%) 86 (12.1%) 96 (13.5%)
25.2%) 184 (26.0%) 174 (24.5%)
52.9%) 377 (53.2%) 373 (52.6%)
4.3 10.6 4.2 10.6 4.3
9.2%) 66 (9.3%) 65 (9.2%)
22.6%) 159 (22.4%) 161 (22.7%)
46.5%) 333 (47.0%) 327 (46.1%)
21.7%) 151 (21.3%) 156 (22.0%)
62.7%) 451 (63.6%) 438 (61.8%)
50.4%) 353 (49.8%) 361 (50.9%)
5.9%) 43 (6.1%) 41 (5.8%)
6.6%) 44 (6.2%) 49 (6.9%)
14.4%) 104 (14.7%) 100 (14.1%)
17.3%) 126 (17.8%) 119 (16.8%)
1.0%) 7 (1.0%) 7 (1.0%)
1.5%) 10 (1.4%) 11 (1.6%)
26.0%) 193 (27.2%) 175 (24.7%)
40.5%) 280 (39.5%) 294 (41.5%)
38.3%) 269 (37.9%) 274 (38.6%)
0.90 1.56 0.85 1.61 0.96
0.51 3.15 0.52 3.15 0.51
5.8 18.2 5.9 18.5 5.7
coronary artery bypass graft; CCS  Canadian Cardiovascular Society;Match
al (N
69.5
399 (
575 (
403 (
41 (
1,178 (
98 (
249 (
89 (
982 (
48 (
38 (
182 (
358 (
750 (
10.6
131 (
320 (
660 (
307 (
889 (
714 (
84 (
93 (
204 (
245 (
14 (
21 (
368 (
574 (
543 (
1.59
3.15
18.4
ABG  saphenous vein graft.
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968matching occurring if the difference in the logits of the
propensity scores was 0.2 the SD of the scores
(caliper width) (19,20). Patients were used only in 1
propensity score matched pair, and those without a
suitable match were excluded from the analysis. After
constructing a propensity-matched cohort, we assessed
the degree of balance in measured covariates between the
DES group and the BMS group. We computed the
standardized difference between the 2 groups for each
type of distribution, with differences of less than 0.1
taken to indicate good balance in the matched cohort.
Kaplan-Meier survival curves between the DES group
and the BMS group were compared using appropriate
statistical tests for matched data (19,20).
In pre-specified subgroup analyses of the outcome TVR,
patients in the DES group and those in the BMS group
were matched on the basis of stent length (long [30 mm]
vs. short [30 mm]), stent diameter (small [3 mm] vs.
large [3 mm]), diabetes status (presence vs. absence), time
from CABG to index PCI (10 years vs. 10 years), and
the logit of the propensity score. Within each of the
subgroups, the reduction in the risk of the outcome was
compared between the DES group and the BMS group
using a Cox regression model, with stent type as the sole
predictor variable. Robust standard errors that accounted for
the clustering of pairs in the matched cohort were obtained
(19,20). The number of patients who would need to be
treated to prevent 1 repeat TVR event was also calculated.
SAS (version 9.1, SAS Institute, Cary, North Carolina)
was used for statistical analyses. A 2-sided p value of 0.05 or
less was considered as statistically significant in the com-
parison of outcomes.
Results
Study sample. From December 1, 2003, to December 31,
2008, 81,871 patients underwent PCI procedures in Ontario,
Canada, and 2,961 patients received stent implantation for
SVG disease. After excluding 263 patients who had both DES
and BMS, 398 patients who had PCI or CABG within 12
months of the index procedure, and considered the initial PCI
among those with multiple procedures during the study period,
our final study cohort included 2,222 patients. Among them, 803
patients received DES and 1,419 patients received BMS. The
baseline characteristics in the DES group and the BMS group
before propensity score matching are shown in Online Table 1.
Baseline characteristic in the propensity-matched cohort. We
dentified 709 matched pairs (N  1,418) who had similar
ikelihood of receiving DES or BMS after propensity score
atching. The mean age was 69 years, 83% were men, and
0% had a history of diabetes (Table 1). The mean duration
rom CABG to the index PCI was 10.6 years. The majority
65.6%) of patients in the DES group received paclitaxel-
luting stents. The median follow-up was 42 months in theES group and 39 months in the BMS group. All the
emographics, clinical, and procedural characteristics were
ell balanced between the matched pairs of DES and BMS
atients. None of the admission or procedure characteristics
ad a standardized difference of the means exceeding 0.1
Table 1).
Target vessel revascularization. Overall, 21% of the patients
receiving a DES and 27.6% of those receiving a BMS required
repeat TVR by 4 years (p  0.004) (Table 2, Fig. 1). The
reduction in repeat TVR associated with DES was observed
at 6 months and remained significantly lower than BMS
throughout the study period. However, the effectiveness of
Table 2. Clinical Outcomes After Index PCI
Outcomes*
BMS
(n  709)
DES
(n  709) p Value†
Target vessel revascularization, % 0.004
6 months 7.8 4.3
1 yr 12.5 8.0
1.5 yrs 16.1 10.6
2 yrs 18.6 12.9
2.5 yrs 21.7 15.6
3 yrs 23.6 16.9
3.5 yrs 25.6 19.5
4 yrs 27.6 21.0
Myocardial infarction, % 0.56
6 months 3.4 2.7
1 yr 6.7 5.1
1.5 yrs 9.0 6.9
2 yrs 10.2 7.9
2.5 yrs 11.8 9.8
3 yrs 14.1 11.7
3.5 yrs 16.4 13.0
4 yrs 18.4 15.0
Death, % 0.17
6 months 6.2 3.1
1 yr 8.5 5.6
1.5 yrs 11.6 7.4
2 yrs 14.2 10.3
2.5 yrs 15.8 11.6
3 yrs 17.2 14.1
3.5 yrs 18.2 16.1
4 yrs 21.1 18.5
Myocardial infarction or death, % 0.09
6 months 8.7 5.4
1 yr 13.5 9.4
1.5 yrs 18.0 12.6
2 yrs 21.1 16.2
2.5 yrs 23.7 18.9
3 yrs 26.4 22.0
3.5 yrs 29.1 24.8
4 yrs 32.6 27.8
*Outcome rates were derived from paired Kaplan-Meier curves. †The p value calculated by
comparing the paired Kaplan-Meier curves.Abbreviations as in Table 1.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 9 , 2 0 1 1 Ko et al.
S E P T E M B E R 2 0 1 1 : 9 6 5 – 7 3 Drug-Eluting Stents for Saphenous Vein Grafts
969DES on reducing TVR varied substantially according to the
pre-specified subgroups (Table 3). For example, the number
of procedures needed to prevent TVR at 4 years was 8 for
patients with diabetes and 7 for patients with stent length
30 mm. In contrast, the number needed to treat was 228
for nondiabetic patients and 51 for patients with shorter
stent length 30 mm (Table 3).
Myocardial infarction and death. The rate of myocardial
infarction during the study period did not differ significantly
between the DES and the BMS groups (p  0.56) (Table 2,
Fig. 2). At 4 years, the rate of death was 18.5% in the DES
group and 21.1% in the BMS group, which is also not
significantly different (p  0.17) (Table 2, Fig. 3). The
Figure 1. TVR Comparing DES and BMS
Kaplan-Meier cumulative event curves for target vessel revascularization (TVR)
drug-eluting stent (DES) group. Light blue line  DES; dark blue line  bare
ple. PCI  percutaneous coronary intervention.
Table 3. Rates and HR of TVR at 4-Years Comparing
Characteristics Matched Pairs (n)
Diabetes
Yes 366
No 343
Stent size, mm
3.0 490
3.0 216
Stent length, mm
30 244
30 465
Time from CABG to index PCI, yrs
10 338
10 221
*Patients were matched based on the logit of the propensity score, dia
and the duration between CABG and index PCI. †Hazard ratios are forCI confidence interval; HR hazard ratio; NNT number needed to treacomposite endpoint of myocardial infarction or death at 4
years occurred in 27.8% in the DES group as compared to
32.6% in the BMS group, but this difference did not reach
statistical significance (p  0.09) (Table 2, Fig. 4).
Discussion
Our study extends previous findings by conducting the
largest observational study to-date evaluating the long-term
safety and effectiveness of DES for the treatment of SVG
disease. First, we did not observe a “catch up” phenomenon
whereby the early benefits of DES in reducing repeat revascu-
larization are attenuated over time. Instead, we found that
propensity-matched cohort showing signiﬁcant reduction in TVR rates in the
l stents (BMS). The p value was estimated using log-rank test for paired sam-
nd BMS, According the Pre-Specified Subgroups*
(%) DES (%) HR (95% CI)† p Value NNT
.4 19.3 0.61 (0.42–0.89) 0.01 8
.8 21.3 0.67 (0.44–1.02) 0.06 228
.3 22.1 0.68 (0.49–0.95) 0.02 16
.3 19.9 0.61 (0.35–1.09) 0.09 29
.1 19.3 0.59 (0.38–0.91) 0.02 7
.0 22.0 0.90 (0.63–1.27) 0.54 51
.0 23.4 0.73 (0.50–1.07) 0.10 15
.3 20.9 0.65 (0.40–1.07) 0.09 19
tatus (presence vs. absence of diabetes), stent diameter; stent length,
S group compared with the BMS group.in the
-metaDES a
BMS
32
21
28
23
34
24
30
26
betes s
the DEt; TVR target vessel revascularization.
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970DES implantation was associated with a significant reduction
in the need for future revascularization compared with BMS
even at 4 years. Second, we found that the reduction of
revascularization was largest among diabetic patients and
patients receiving stent length 30 mm, where fewer than 10
ES implantations could prevent a TVR event. Finally,
espite previous concerns regarding the potential risks of DES
n SVGs, no increased risk of myocardial infarction or death
as observed at long-term follow-up.
Despite the increased use of arterial grafting, SVGs
emain the most commonly used conduit for CABG sur-
ery. Graft atherosclerosis remains a common problem and
Figure 2. MI Comparing DES and BMS
Kaplan-Meier cumulative event curves for myocardial infarction (MI) in the pro
DES. Light blue line  DES; dark blue line  BMS. The p value was estimate
Figure 3. Death Comparing DES and BMS
Kaplan-Meier cumulative event curves for MI in the propensity-matched cohor
Light blue line  DES; dark blue line  BMS. The p value was estimated using logt is well documented that BMS treatment of SVG lesions
s suboptimal because of increased risk of restenosis and
raft occlusion (21). Therefore, whether treatment with
ES is associated with added benefits in SVG interventions
as been a subject of intense debate and the focus of
ngoing randomized trials (8). To date, data from 2 small
andomized trials comparing DES and BMS for the treatment
f SVG lesions have yielded conflicting results (6–8,22). The
RISC trial randomized 38 patients treated with sirolimus-
luting stents and 37 patients treated with BMS. At 30
onths, the benefits of DES in reducing repeating TVR were
ost and mortality rates were higher with DES (8). In the SOS
y-matched cohort showing no signiﬁcant increase in MI rates associated with
g log-rank test for paired sample. Abbreviations as in Figure 1.
ing no signiﬁcant increase in mortality rates associated with DES.pensitt show
-rank test for paired sample. Abbreviations as in Figures 1 and 2.
I
I
(
p
a
a
c
s
r
S
a
r
c
d
r
d
r
d
w
i
g
d
S
e
t
t
r
a
a
t
n
w
s
i
B
h
n
n
v
s
a
e
t
d
r
t
ng the
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 9 , 2 0 1 1 Ko et al.
S E P T E M B E R 2 0 1 1 : 9 6 5 – 7 3 Drug-Eluting Stents for Saphenous Vein Grafts
971trial that randomized 39 patients treated with paclitaxel-eluting
stents and 41 patients treated with BMS, fewer target revas-
cularizations and no significant increase in myocardial infarc-
tion or death was observed in the DES group (8). The
SAR-CABG (Is Drug-Eluting Stenting Associated with
mproved Results in Coronary Artery Bypass Grafts) study
23) was recently presented. The investigators randomized 610
atients undergoing SVG interventions to DES versus BMS
nd found a 50% reduction in target lesion revascularization
ssociated with DES without increased rates of adverse out-
omes at 12-months follow-up (23).
Brodie et al. (9) performed 1 of the largest observational
tudies analyzing SVG interventions among 785 patients
eceiving DES and 343 patients receiving BMS in the
TENT (Strategic Transcatheter Evaluation of New Ther-
pies) registry. At 2 years, the early benefits of DES on
epeat TVR were largely attenuated and no longer signifi-
antly different compared with BMS. In contrast, we
emonstrated that DES use was associated with a sustained
eduction of TVR throughout the study period. This
iscrepancy may be explained by the fact that late repeat
evascularization after SVG interventions is often related to
isease progression in nonstented areas (24). Therefore, it
as believed that the “catch up” phenomenon was due to an
mbalance in degenerative SVGs between the treatment
roups (9). Although we were unable to quantify the degree of
egeneration in SVGs, our study accounted for the age of
VGs in the propensity match, thereby minimizing the differ-
nce in disease progression in the nonstented segments be-
ween the 2 treatment groups. Our results suggest that DES
reatment can provide a significant and sustained benefit in
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Figure 4. MI or Death Comparing DES and BMS
Kaplan-Meier cumulative event curves for MI in the propensity-matched cohor
Light blue line  DES; dark blue line  BMS. The p value was estimated usieducing repeat revascularization in SVG interventions.The large number of patients included in our study
fforded an opportunity to perform pre-specified subgroup
nalyses that provided additional insights. Consistent with
he observations regarding DES treatment of native coro-
ary arteries, the association of DES and TVR reduction
as largest among diabetics and patients requiring longer
tents. By contrast, we did not observe significant difference
n TVR among nondiabetic patients treated with DES and
MS in SVG interventions at 4 years. The less robust
azard ratios and the similar TVR rates at 4 years in the
ondiabetic subgroup suggest that the benefits of DES may
ot be as durable as other subgroups.
Another important finding of our paper was the obser-
ation that myocardial infarction and mortality rates did not
ignificantly differ in the DES group and the BMS group at
follow-up period of 4 years. In fact, the composite
ndpoint of myocardial infarction and death was lower in
he DES group compared with the BMS group, though it
id not achieve statistical significance. Nevertheless, our
esults are reassuring in demonstrating the safety of DES
reatment in SVG interventions in routine clinical practice.
Study limitations. First, our study should be placed in the
context of local interventional practice. Ontario has a
universal policy whereby all patients over 65 years of age are
eligible to receive clopidogrel for 1 year at minimal cost. We
have previously demonstrated that more than 70% patients
are still compliant with clopidogrel at 6 months (25).
Accordingly, the safety profile of DES that was observed in
our study may not be generalizable to all healthcare settings.
Second, observational studies are subject to the influence of
confounding. However, the availability of many clinical
2.5 3 3.5 4
dex PCI
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15                  443                        373                      308                     208   
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p = 0.09 
ing no signiﬁcant increase in MI or death rates associated with DES.
log-rank test for paired sample. Abbreviations as in Figures 1 and 2.2
fter In
            4
            5
t showvariables and a large sample size allowed us to perform a
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972detailed propensity score matched analysis that accounted
for all the important potential confounding variables. Fi-
nally, we used myocardial infarction after PCI as a safety
endpoint because we did not have information on late stent
thrombosis in our database. Therefore, although we did not
observe significant difference in the rate of myocardial
infarction between the treatment groups, we cannot defi-
nitely exclude a higher rate of stent thrombosis associated
with DES.
Conclusions
DES is associated with significant reduction in the need for
repeat revascularization compared with BMS in SVG inter-
ventions, and the absolute reduction is largest in patients who
are diabetics or have longer lesions. DES use is associated not
with an increased risk of myocardial infarction or death
compared with BMS. While we await the results of larger
randomized clinical trials with long-term follow-up, our
results should lend support to the contemporary practice in
implanting DES among appropriate patients with SVG
lesions.
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APPENDIX
For the baseline characteristics in the DES group and the BMS group
before propensity score matching, please see the online version of this
paper.
